In addition to its unique high expression in PCA, PSMA expression has been observed in tumor neovasculature of almost all solid tumors, and not in normal vasculature, supporting the possibility that PSMA-directed therapies can represent a novel anti-angiogenic strategy that may aid in the management of diverse solid tumors [14, 20]. The gene discussed is FOLH1; the disease is neoplasm.